Press Release Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results 7 hours ago
Press Release Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Aug 6